Shopping Cart 0
Cart Subtotal
USD 0

Benign Prostatic Hyperplasia-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Benign Prostatic Hyperplasia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H1 2017, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 6, 3, 1, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).

The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Benign Prostatic Hyperplasia-Overview

Benign Prostatic Hyperplasia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Benign Prostatic Hyperplasia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Benign Prostatic Hyperplasia-Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

AndroScience Corp

Aphios Corp

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GL Pharm Tech Corp

Hanmi Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Monosol Rx LLC

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

SOM Biotech SL

Sophiris Bio Inc

Vantia Therapeutics

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Benign Prostatic Hyperplasia-Drug Profiles

(dutasteride + tadalafil)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(solifenacin succinate + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-68692-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASC-JM.X2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCWPE-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-1447-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadanafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedovapagon-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexapotide triflutate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKM-1202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-1AD3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCS-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-403-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8430506-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0131632-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-40542-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-2391-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-2393-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sperol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talaporfin sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride CR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride DR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

topsalysin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TT-701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YBH-1603-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YOB-1604-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Benign Prostatic Hyperplasia-Dormant Projects

Benign Prostatic Hyperplasia-Discontinued Products

Benign Prostatic Hyperplasia-Product Development Milestones

Featured News & Press Releases

May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe

May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe

Mar 29, 2017: Nymox Provides Update on Fexapotide Development

Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug-Fadanafil

Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692

May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting

Apr 01, 2015: Nymox Announces Phase 3 BPH Studies

Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints

Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH

Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study

Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Addex Therapeutics Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by AndroScience Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Aphios Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by BCWorld Pharm Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Biolab Farmaceutica Ltda, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Curadis GmbH, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by GL Pharm Tech Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by MEI Pharma Inc, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Meiji Seika Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Mezzion Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Monosol Rx LLC, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Nymox Pharmaceutical Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by OPKO Health Inc, H1 2017

Benign Prostatic Hyperplasia-Pipeline by SK Chemicals Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by SOM Biotech SL, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Sophiris Bio Inc, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Vantia Therapeutics, H1 2017

Benign Prostatic Hyperplasia-Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Yungjin Pharm Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Dormant Projects, H1 2017

Benign Prostatic Hyperplasia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Benign Prostatic Hyperplasia-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Addex Therapeutics Ltd, AndroScience Corp, Aphios Corp, BCWorld Pharm Co Ltd, Biolab Farmaceutica Ltda, Chong Kun Dang Pharmaceutical Corp, Curadis GmbH, Dongkook Pharmaceutical Co Ltd, GL Pharm Tech Corp, Hanmi Pharmaceuticals Co Ltd, Health Ever Bio-Tech Co Ltd, Jeil Pharmaceutical Co Ltd, Kaken Pharmaceutical Co Ltd, MEI Pharma Inc, Meiji Seika Pharma Co Ltd, Mezzion Pharma Co Ltd, Monosol Rx LLC, Nymox Pharmaceutical Corp, Ono Pharmaceutical Co Ltd, OPKO Health Inc, SK Chemicals Co Ltd, SOM Biotech SL, Sophiris Bio Inc, Vantia Therapeutics, XuanZhu Pharma Co Ltd, Yungjin Pharm Co Ltd

Company Profile

Company Profile Title

Benign Prostatic Hyperplasia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H1 2017, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 6, 3, 1, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).

The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Benign Prostatic Hyperplasia-Overview

Benign Prostatic Hyperplasia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Benign Prostatic Hyperplasia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Benign Prostatic Hyperplasia-Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

AndroScience Corp

Aphios Corp

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GL Pharm Tech Corp

Hanmi Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Monosol Rx LLC

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

SOM Biotech SL

Sophiris Bio Inc

Vantia Therapeutics

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Benign Prostatic Hyperplasia-Drug Profiles

(dutasteride + tadalafil)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(solifenacin succinate + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-68692-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASC-JM.X2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCWPE-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-1447-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadanafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedovapagon-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexapotide triflutate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKM-1202-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-1AD3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCS-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-403-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8430506-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0131632-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-40542-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-2391-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-2393-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sperol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talaporfin sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride CR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride DR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

topsalysin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TT-701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YBH-1603-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YOB-1604-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Benign Prostatic Hyperplasia-Dormant Projects

Benign Prostatic Hyperplasia-Discontinued Products

Benign Prostatic Hyperplasia-Product Development Milestones

Featured News & Press Releases

May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe

May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe

Mar 29, 2017: Nymox Provides Update on Fexapotide Development

Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug-Fadanafil

Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692

May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting

Apr 01, 2015: Nymox Announces Phase 3 BPH Studies

Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints

Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH

Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study

Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Addex Therapeutics Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by AndroScience Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Aphios Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by BCWorld Pharm Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Biolab Farmaceutica Ltda, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Curadis GmbH, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by GL Pharm Tech Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by MEI Pharma Inc, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Meiji Seika Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Mezzion Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Monosol Rx LLC, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Nymox Pharmaceutical Corp, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by OPKO Health Inc, H1 2017

Benign Prostatic Hyperplasia-Pipeline by SK Chemicals Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by SOM Biotech SL, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Sophiris Bio Inc, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Vantia Therapeutics, H1 2017

Benign Prostatic Hyperplasia-Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Pipeline by Yungjin Pharm Co Ltd, H1 2017

Benign Prostatic Hyperplasia-Dormant Projects, H1 2017

Benign Prostatic Hyperplasia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Benign Prostatic Hyperplasia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Addex Therapeutics Ltd, AndroScience Corp, Aphios Corp, BCWorld Pharm Co Ltd, Biolab Farmaceutica Ltda, Chong Kun Dang Pharmaceutical Corp, Curadis GmbH, Dongkook Pharmaceutical Co Ltd, GL Pharm Tech Corp, Hanmi Pharmaceuticals Co Ltd, Health Ever Bio-Tech Co Ltd, Jeil Pharmaceutical Co Ltd, Kaken Pharmaceutical Co Ltd, MEI Pharma Inc, Meiji Seika Pharma Co Ltd, Mezzion Pharma Co Ltd, Monosol Rx LLC, Nymox Pharmaceutical Corp, Ono Pharmaceutical Co Ltd, OPKO Health Inc, SK Chemicals Co Ltd, SOM Biotech SL, Sophiris Bio Inc, Vantia Therapeutics, XuanZhu Pharma Co Ltd, Yungjin Pharm Co Ltd